Alnylam Hit Hard As Investors Forced To Revise Future Profit Expectations [Seeking Alpha]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Seeking Alpha
The TTR business will likely remain "noisy" in the first half of 2026, but Amvuttra continues to gain share, and management guidance for 2026 was above expectations. Management alarmed the Street earlier this year with long-term spending guidance that was considerably higher than expected; management continues to prioritize R&D to realize the company's full long-term potential. 2026 is a 'sleeper year' for clinical data, but early-stage readouts from ALN-6400, ALN-HTT02, and ALN-2232 could provide upside catalysts. Fair value now stands at $456 per share, with about 70% of that tied to the TTR franchise, but meaningful longer-term upside is tied to positive clinical trial readouts. anusorn nakdee/iStock via Getty Images It's been a rough go for Alnylam Pharmaceuticals ( ALNY ) since October 2025, with the shares down almost 40% from an all-time high. While it is typically clinical failures that hit biotechs hard, Alnylam is in that awkward biopharma adolescence where invest
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Alnylam Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Chardan Capital from $475.00 to $425.00. They now have a "buy" rating on the stock.MarketBeat
- Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its "buy" rating reaffirmed by analysts at Bank of America Corporation.MarketBeat
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Needham & Company LLC from $529.00 to $510.00. They now have a "buy" rating on the stock.MarketBeat
ALNY
Earnings
- 2/12/26 - Beat
ALNY
Sec Filings
- 2/12/26 - Form S-8
- 2/12/26 - Form 10-K
- 2/12/26 - Form 8-K
- ALNY's page on the SEC website